Among the cohort of 333 patients that underwent treatment with anti-PD-1 or anti-PD-L1 antibody therapy, 115 fatalities were ascribed to pneumonia, accounting for 35% of the cases. This evidence concerns the gene PDCD1 and pneumonia.